Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGES2 | Q9H7Z7 | 8/20 | 0.46 |
| ▸ | ACLY | P53396 | 1/20 | 0.43 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.42 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1838256 | 0.89 | ACLY (0.50) | PTGES2ACLYTRPV4POLBMEN1 | |
| SCHEMBL1679612 | 0.85 | PDCD1 (0.50) | PTGES2TRPV4POLBMEN1KMT2A | |
| SCHEMBL29825398 | 0.85 | PDCD1 (0.50) | PTGES2TRPV4POLBMEN1KMT2A | |
| SCHEMBL9921408 | 0.83 | HMGCR (0.47) | PTGES2ACLYTRPV4SLC6A2SLC6A4 | |
| SCHEMBL7435306 | 0.82 | ACLY (0.43) | PTGES2ACLYTRPV4POLBKDM4C | |
| SCHEMBL1569795 | 0.81 | TAAR1 (0.61) | — | |
| SCHEMBL20761848 | 0.81 | HTT (0.46) | PTGES2ACLYTRPV4SLC6A2SLC6A4 | |
| SCHEMBL11503227 | 0.81 | PTGES2 (0.46) | PTGES2ACLYTRPV4MEN1KMT2A | |
| SCHEMBL11313806 | 0.80 | MAPT (0.59) | PTGES2TRPV4MEN1KMT2AKDM4C | |
| Hydrochloric Acid SCHEMBL1571623 | 0.80 | TAAR1 (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190055212-A1 | HISTONE DEMETHYLASE INHIBITORS | GWALTNEY STEPHEN (US) | 2019-02-21 | — | — | US | disclosed |
| US-8263656-B2 | Substituted aminotetralines | HOFFMANN-LA ROCHE INC. (US) | 2012-09-11 | — | — | US | disclosed |
| WO-2010018109-A2 | SUBSTITUTED AMINOTETRALINES | F. HOFFMANN-LA ROCHE AG (CH) | 2010-02-18 | — | — | WO | disclosed |
| US-20100041713-A1 | SUBSTITUTED AMINOTETRALINES | FIROOZNIA FARIBORZ | 2010-02-18 | — | — | US | disclosed |
| EP-1606268-A1 | HETEROCYCLIC KINASE INHIBITORS | Abbott Laboratories (US) | 2005-12-21 | — | — | EP | disclosed |
| WO-2004076424-A1 | HETEROCYCLIC KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2004-09-10 | — | — | WO | disclosed |
| EP-0874826-A1 | NAPHTHALENE QUINOLINES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997024331-A1 | NAPHTHALENE QUINOLINES HAVING LEUKOTRIENE-ANTAGONISTIC ACTION | LABORATORIOS MENARINI S.A. (ES) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041713-A1 | SUBSTITUTED AMINOTETRALINES | HRH4, HRH1, HRH2 | PTGES2 428/4885ACLY 2509/4885TRPV4 1078/4885 |
| US-20190055212-A1 | HISTONE DEMETHYLASE INHIBITORS | KDM1B, KDM6B, KDM5B | PTGES2 3335/4885ACLY 1832/4885TRPV4 4771/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.